{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:32:16Z","timestamp":1780050736309,"version":"3.53.1"},"publisher-location":"Cham","reference-count":50,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030410070","type":"print"},{"value":"9783030410087","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-41008-7_14","type":"book-chapter","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T12:08:46Z","timestamp":1587038926000},"page":"271-276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hepatobiliary Adverse Events"],"prefix":"10.1007","author":[{"given":"Hamzah","family":"Abu-Sbeih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","unstructured":"Foller S, Oppel-Heuchel H, Fetter I, Winkler Y, Grimm MO. [Adverse events of immune checkpoint inhibitors]. Urologe A. 2017;56:486\u201391","DOI":"10.1007\/s00120-017-0342-3"},{"key":"14_CR2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/phar.2035","volume":"37","author":"AK Ali","year":"2017","unstructured":"Ali AK, Watson DE. Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy. 2017;37:1383\u201390.","journal-title":"Pharmacotherapy"},{"key":"14_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u201330.","journal-title":"J Clin Oncol"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/CMR.0b013e32835c7e68","volume":"23","author":"SG Bernardo","year":"2013","unstructured":"Bernardo SG, Moskalenko M, Pan M, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res. 2013;23:47\u201354.","journal-title":"Melanoma Res"},{"key":"14_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"14_CR6","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","volume":"21","author":"SJ O\u2019Day","year":"2010","unstructured":"O\u2019Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21:1712\u20137.","journal-title":"Ann Oncol"},{"key":"14_CR7","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet"},{"key":"14_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"14_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol"},{"key":"14_CR10","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"14_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190\u2013209.","journal-title":"Eur J Cancer"},{"key":"14_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","volume":"13","author":"AJ Eertwegh van den","year":"2012","unstructured":"van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:509\u201317.","journal-title":"Lancet Oncol"},{"key":"14_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"key":"14_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"14_CR15","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol. 2017;35:3815\u201322.","journal-title":"J Clin Oncol"},{"key":"14_CR16","doi-asserted-by":"crossref","unstructured":"De Martin E, Michot JM, Papouin B, et al. Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors. J Hepatol 2018;68(6):1181\u20131190.","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"14_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10637-013-9939-6","volume":"31","author":"KW Kim","year":"2013","unstructured":"Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013;31:1071\u20137.","journal-title":"Invest New Drugs"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691\u20137.","journal-title":"J Clin Oncol"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1148\/rg.352140121","volume":"35","author":"JJ Kwak","year":"2015","unstructured":"Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35:424\u201337.","journal-title":"Radiographics"},{"key":"14_CR20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39:1075\u201384.","journal-title":"Am J Surg Pathol"},{"key":"14_CR21","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","volume":"29","author":"KD Chmiel","year":"2011","unstructured":"Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29:e237\u201340.","journal-title":"J Clin Oncol"},{"key":"14_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11894-017-0540-6","volume":"19","author":"P Cramer","year":"2017","unstructured":"Cramer P, Bresalier RS. Gastrointestinal and hepatic complications of immune checkpoint inhibitors. Curr Gastroenterol Rep. 2017;19:3.","journal-title":"Curr Gastroenterol Rep"},{"key":"14_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"14_CR24","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353.","journal-title":"JAMA Oncol"},{"key":"14_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3:1185\u201392.","journal-title":"Cancer Immunol Res"},{"key":"14_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1159\/000471480","volume":"10","author":"K Imafuku","year":"2017","unstructured":"Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Successful treatment of sudden hepatitis induced by long-term nivolumab administration. Case Rep Oncol. 2017;10:368\u201371.","journal-title":"Case Rep Oncol"},{"key":"14_CR27","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931\u20139.","journal-title":"Hepatology"},{"key":"14_CR28","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10620-012-2140-5","volume":"57","author":"DE Kleiner","year":"2012","unstructured":"Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233\u201340.","journal-title":"Dig Dis Sci"},{"key":"14_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1148\/rg.244035719","volume":"24","author":"KJ Mortele","year":"2004","unstructured":"Mortele KJ, Segatto E, Ros PR. The infected liver: radiologic-pathologic correlation. Radiographics. 2004;24:937\u201355.","journal-title":"Radiographics"},{"key":"14_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40134-017-0256-2","volume":"5","author":"G Widmann","year":"2016","unstructured":"Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep. 2016;5:59.","journal-title":"Curr Radiol Rep"},{"key":"14_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.","journal-title":"Front Pharmacol"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.crad.2017.04.003","volume":"72","author":"F Alessandrino","year":"2017","unstructured":"Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol. 2017;72:521\u201333.","journal-title":"Clin Radiol"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/PAS.0000000000000759","volume":"41","author":"J Everett","year":"2017","unstructured":"Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol. 2017;41:134\u20137.","journal-title":"Am J Surg Pathol"},{"key":"14_CR34","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965\u201373.","journal-title":"Mod Pathol"},{"key":"14_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","volume":"71","author":"DM Karamchandani","year":"2018","unstructured":"Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists\u2019 perspective. J Clin Pathol. 2018;71:665\u201371.","journal-title":"J Clin Pathol"},{"key":"14_CR36","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. \nhttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf\n\n. 2018."},{"key":"14_CR37","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"14_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019;17:255\u201389.","journal-title":"J Natl Compr Canc Netw"},{"key":"14_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.","journal-title":"J Immunother Cancer"},{"key":"14_CR40","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006\u201317.","journal-title":"N Engl J Med"},{"key":"14_CR41","doi-asserted-by":"publisher","first-page":"1027323","DOI":"10.1155\/2018\/1027323","volume":"2018","author":"Q Su","year":"2018","unstructured":"Su Q, Zhang XC, Zhang CG, Hou YL, Yao YX, Cao BW. Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis. J Immunol Res. 2018;2018:1027323.","journal-title":"J Immunol Res"},{"key":"14_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tang T, Lu Y, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7:31.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"14_CR43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","volume":"19","author":"J George","year":"2019","unstructured":"George J, Bajaj D, Kesavan S, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology. 2019;19(4):587\u201394.","journal-title":"Pancreatology"},{"key":"14_CR44","first-page":"84","volume":"41","author":"JM Michot","year":"2018","unstructured":"Michot JM, Ragou P, Carbonnel F, et al. Significance of immune-related lipase increase induced by antiprogrammed death-1 or death ligand-1 antibodies: a brief communication. J Immunother (Hagerstown, Md: 1997). 2018;41:84\u20135.","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"14_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1503\/cjs.015015","volume":"59","author":"JA Greenberg","year":"2016","unstructured":"Greenberg JA, Hsu J, Bawazeer M, et al. Clinical practice guideline: management of acute pancreatitis. Can J Surg. 2016;59:128\u201340.","journal-title":"Can J Surg"},{"issue":"5","key":"14_CR46","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/CMR.0000000000000611","volume":"29","author":"J Kohlmann","year":"2019","unstructured":"Kohlmann J, Wagenknecht D, Simon JC, Ziemer M. Immune-related pancreatitis associated with checkpoint blockade in melanoma. Melanoma Res. 2019;29(5):549\u201352.","journal-title":"Melanoma Res"},{"key":"14_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2217\/imt-2017-0126","volume":"10","author":"T Prasanna","year":"2018","unstructured":"Prasanna T, McNeil CM, Nielsen T, Parkin D. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy. Immunotherapy. 2018;10:171\u20135.","journal-title":"Immunotherapy"},{"key":"14_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","volume":"7","author":"H Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H, Tran CN, Ge PS, et al. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer. 2019;7:118.","journal-title":"J Immunother Cancer"},{"key":"14_CR49","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","volume":"13","author":"JH Cho","year":"2018","unstructured":"Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer. J Thorac Oncol. 2018;13:e34\u2013e6.","journal-title":"J Thorac Oncol"},{"key":"14_CR50","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investig New Drugs. 2017;35:529\u201336.","journal-title":"Investig New Drugs"}],"container-title":["Advances in Experimental Medicine and Biology","Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-41008-7_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T12:27:32Z","timestamp":1587040052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-41008-7_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030410070","9783030410087"],"references-count":50,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-41008-7_14","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"17 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}